全文获取类型
收费全文 | 43072篇 |
免费 | 3013篇 |
国内免费 | 148篇 |
专业分类
耳鼻咽喉 | 467篇 |
儿科学 | 1378篇 |
妇产科学 | 1176篇 |
基础医学 | 5925篇 |
口腔科学 | 493篇 |
临床医学 | 6272篇 |
内科学 | 8251篇 |
皮肤病学 | 712篇 |
神经病学 | 4384篇 |
特种医学 | 812篇 |
外国民族医学 | 1篇 |
外科学 | 3457篇 |
综合类 | 763篇 |
一般理论 | 42篇 |
预防医学 | 5018篇 |
眼科学 | 894篇 |
药学 | 3004篇 |
中国医学 | 80篇 |
肿瘤学 | 3104篇 |
出版年
2023年 | 223篇 |
2022年 | 472篇 |
2021年 | 865篇 |
2020年 | 479篇 |
2019年 | 800篇 |
2018年 | 931篇 |
2017年 | 721篇 |
2016年 | 804篇 |
2015年 | 975篇 |
2014年 | 1310篇 |
2013年 | 1994篇 |
2012年 | 3014篇 |
2011年 | 3168篇 |
2010年 | 1605篇 |
2009年 | 1557篇 |
2008年 | 2847篇 |
2007年 | 3068篇 |
2006年 | 3150篇 |
2005年 | 3098篇 |
2004年 | 3014篇 |
2003年 | 2833篇 |
2002年 | 2622篇 |
2001年 | 376篇 |
2000年 | 281篇 |
1999年 | 377篇 |
1998年 | 483篇 |
1997年 | 417篇 |
1996年 | 380篇 |
1995年 | 361篇 |
1994年 | 268篇 |
1993年 | 298篇 |
1992年 | 214篇 |
1991年 | 207篇 |
1990年 | 186篇 |
1989年 | 187篇 |
1988年 | 191篇 |
1987年 | 153篇 |
1986年 | 131篇 |
1985年 | 150篇 |
1984年 | 190篇 |
1983年 | 186篇 |
1982年 | 237篇 |
1981年 | 176篇 |
1980年 | 185篇 |
1979年 | 110篇 |
1978年 | 107篇 |
1977年 | 113篇 |
1976年 | 86篇 |
1975年 | 71篇 |
1974年 | 78篇 |
排序方式: 共有10000条查询结果,搜索用时 13 毫秒
91.
92.
Dr. A. Belluzzi MD C. Brignola MD M. Campieri MD E. P. Camporesi BS P. Gionchetti MD F. Rizzello MD C. Belloli MD G. De Simone MD S. Boschi MD M. Miglioli MD L. Barbara MD 《Digestive diseases and sciences》1994,39(12):2589-2594
Fish oil has been recently proposed as a possible effective treatment in inflammatory bowel disease (IBD); however, a lot of annoying side effects (ie, belching, halitosis, diarrhea, etc) affect patient compliance. We carried out a study of patient tolerance in a group of Crohn's disease (CD) patients with a new fish oil derivative consisting of 500-mg capsules of eicosapentaenoic-docosahexaenoic (EPA 40%-DHA 20%), a free fatty acid mixture (Purepa), and we also evaluated its incorporation into phospholipids, both in plasma and in red cell membranes. Five groups of 10 CD patients in remission received nine Purepa capsules daily in four different preparations (A: uncoated, B: coated, pH 5.5; C: coated, pH 5.5, 60 min time release; D: coated, pH 6.9) and 12 × 1-g capsules daily of a triglyceride preparation (Max-EPA, EPA 18%-DHA 10%), respectively. We coated three of the four Purepa preparations in order to delay the release of contents in an attempt to minimize the side effects. After six weeks of treatment, the group taking Purepa capsules, coated, pH 5.5, 60 min time release (group C) showed the best incorporation of EPA and DHA in red blood cell phospholipid membranes (EPA from 0.2 to 4.4%, DHA from 3.7 to 6.3%), and no side effects were registered, whereas in all other groups side effects were experienced in 50% or more of subjects. This new preparation will make it possible to treat patients for long periods. 相似文献
93.
The kinetics of the addition reaction of methacrylic acid (1) and 2,2-bis[4-(2,3-epoxypropoxy)-phenyl]propane catalyzed by tertiary aliphatic amines, aromatic N-heterocycles and quaternary ammonium salts, respectively, was studied in bulk with equimolar amounts of functional groups from room temperature to 120°C. A reaction order of 1,5 with regard to the conversion of epoxy as well as carboxylic groups was observed. This can be explained assuming the formation of an ammonium alkoxide ion pair by the equilibrium reaction of an epoxy group with ammonium carboxylate and the irreversible consecutive reaction of the ion pair with (1) under formation of 2-hydroxyester groups and regeneration of ammonium carboxylate. The reaction rate constants increase linearly with the concentration of the catalyst and increase with increasing basicity of alkylpyridines. The advantage of the aromatic N-heterocyclic catalysts consists in their stability to peroxides which are ingredients of preparations together with the epoxy methacrylate Bis-GMA, e. g. in dental composites and adhesives. 相似文献
94.
95.
96.
Barbara L. Shacklett PhD 《Current infectious disease reports》2006,8(3):248-253
It has been known for many years that not all individuals who are repeatedly exposed to HIV-1 show evidence of viral replication,
seroconvert, and eventually develop disease. Quite apart from those who seroconvert but progress slowly to AIDS (ie, slow
progressors, longterm nonprogressors, elite controllers), these rare, exposed seronegatives either resist infection or harbor
extremely low levels of virus that may be detected only using ultrasensitive methods (occult infection). The correlates of
protection that confer this unique status to a tiny minority of HIV-exposed individuals remain a subject of intense interest,
investigation, and controversy, as no single genetic or immunologic parameter has yet been able to fully explain this phenomenon.
However, there is general consensus that studying these individuals may provide invaluable information to aid in the design
of vaccines and therapeutic approaches. This review describes the major findings on this important topic, with a focus on
immunologic studies. 相似文献
97.
98.
99.
100.
John J. Carey Miriam F. Delaney Thomas E. Love Bradford J. Richmond Barbara A. Cromer Paul D. Miller Martha Manilla-McIntosh Steven A. Lewis Charles L. Thomas Angelo A. Licata 《Journal of clinical densitometry》2007,10(4):11-358
Central dual-energy X-ray absorptiometry (DXA) is the gold standard for non-invasive measurement of bone mineral density (BMD). Using this value and subject demographics, DXA software calculates T-scores and Z-scores. Professional society guidelines for the management of osteoporosis are based on T-scores and Z-scores, rather than on the actual BMD value. Although one expects T-scores and Z-scores to be very similar in young men and women for any given BMD measurement, little literature exists on this issue. Our clinical experience shows that some younger adult individuals (premenopausal women and men younger than 50 yr) have larger than expected difference between their DXA T-score and Z-score. This cross-sectional study evaluates the extent of this discordance between Z-scores and T-scores in a sample of 4275 men and women aged 20–49 yr. All subjects were scanned by central DXA using equipment manufactured by GE Lunar, GE, Madison, WI, or Hologic, Inc., Bedford, MA. Significant differences between Z-scores and T-scores were seen within individuals at the lumbar spine, total hip, femoral neck, and trochanter (p value < 0.001) for both DXA systems. Although these differences were less than half a standard deviation (SD) in most instances, the magnitude of difference was substantial at times, being 1 or more SD in up to 11% of cases (range: −1.95 to +1.54 SD). The smallest differences were seen at the total hip and the largest differences were seen at the femoral neck for both technologies. This is in part because there is no single standard Z-score definition, resulting in different methods of calculation across, and even within, DXA manufacturers. Standardization of Z-score definition and method of calculation is indicated. DXA Z-scores should be interpreted with caution in men and women aged 20–50 yr. 相似文献